CheckMate 214 Updates: Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced RCC
oncodaily - First-line treatment for advanced renal cell carcinoma has changed substantially with the use of immune checkpoint inhibitor-based regimens. Long-term follow-up is important to show whether these early survival and response […]
AI Summary: Long‑term CheckMate‑214 data comparing nivolumab plus ipilimumab against sunitinib in advanced renal cell carcinoma show sustained survival benefits for the immunotherapy combination at nine years. The follow‑up reinforces durable responses in a defined subgroup, helping clinicians refine long‑term treatment sequencing and expectations for metastatic RCC.
Related Stories
Teclistamab shows survival benefit prompting earlier use discussions / 14 days
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 2 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 2 months
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 2 months
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 2 months
Romiplostim reduces chemotherapy‑induced thrombocytopenia and prevents recurrence / 3 months
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Vaccine Safety, Medicare Advantage (not listed), Biotech, Infectious Disease and look for the RSS link.
StackHealth Time Machine